Medii Opens Case Consultation Window for Primary Care Physicians to Aim for Early Diagnosis and Treatment Optimization of Muscular Dystrophy
Medii Inc. launched a free consultation desk for pediatric muscular dystrophy on 'Medii E-Consult'. This connects primary care doctors with expert pediatric neurologists to facilitate early diagnosis and optimal treatment.
📋 Article Processing Timeline
- 📰 Published: April 24, 2026 at 19:10
- 🔍 Collected: April 24, 2026 at 10:31
- 🤖 AI Analyzed: April 25, 2026 at 04:23 (17h 51m after Collected)
Medii Inc. (Headquarters: Shinjuku-ku, Tokyo, CEO & Physician: Yuki Yamada, hereinafter Medii) has opened a case consultation window for pediatric muscular dystrophy on its specialist consultation service for doctors, 'Medii E-Consult,' in collaboration with a team of pediatric neurologists.
This window aims to achieve early diagnosis and treatment optimization in pediatric muscular dystrophy, which requires high expertise for diagnosis and determining treatment policies. It establishes an environment where primary care physicians nationwide can directly consult with expert specialists.
Background
Muscular dystrophy is a designated intractable disease where muscle fibers degenerate and necrose due to genetic mutations, leading to progressive muscle weakness. There are multiple disease types, each being a rare disease with a small number of patients, and the onset timing and progression speed vary widely.
Particularly in childhood, initial symptoms such as delayed motor development or a tendency to fall can be difficult to distinguish from individual differences during the growth process. Therefore, depending on the disease type, delays in diagnosis—sometimes taking several years to reach a definitive diagnosis—have become a significant issue. Additionally, because physical and functional growth is remarkable during childhood, extremely high expertise is required to select optimal treatments and conduct long-term follow-ups according to age and developmental stages. Furthermore, providing explanations to patients and their families, such as future outlooks, requires the latest knowledge and multifaceted consideration.
In recent years, new treatment options based on genes and molecular mechanisms have emerged for certain disease types. These treatments often have specified indication conditions regarding age, disease stage, and genotype, making early diagnosis and appropriate judgment crucial.
On the other hand, the number of pediatric neurologists familiar with muscular dystrophy is limited nationwide, and it has been pointed out that access to specialists varies by region and facility. There is a need to establish a system where primary care physicians can swiftly access expert knowledge at the stage when clinical suspicion initially arises.
To address these challenges, we have opened this consultation window.
Overview of the Case Consultation Window
This window is a consultation service for doctors that primary care physicians treating pediatric muscular dystrophy can use anonymously and free of charge. Specialists provide advice based on their experience and knowledge in response to clinical questions held by primary care physicians.
Support is provided from an expert perspective at every stage of medical care, including differential diagnosis, consideration of treatment policies, interpretation of test results, age-appropriate follow-up, and methods of explaining to patients and families.
While currently targeting the pediatric phase, we plan to expand correspondence to adult clinical departments in the future.
[Related Initiatives]
Utilizing Medii E-Consult, Medii is also working in collaboration with the Japanese Society of Child Neurology to build a side-effect management system for regenerative medical products for Duchenne muscular dystrophy.
[Details] Press release dated April 23, 2026: Joint construction of a 'doctor-to-doctor collaboration system' with the Japanese Society of Child Neurology aimed at safety management of regenerative medical products for Duchenne muscular dystrophy (https://medii.jp/news/20260423)
◾️ Pediatric Muscular Dystrophy Specialist Consultation Window
URL: https://x.medii.jp/65b9bf
*This service is exclusively for doctors, and membership registration is required to use it.
*Membership registration and use of the service will continue to be provided free of charge.
◾️ Expert Specialists in Charge of This Consultation Window
National Center of Neurology and Psychiatry (NCNP), Director of Translational Medical Center / Director of Pediatric Neurology
Dr. Hirofumi Komaki
- Board Member of the Japanese Society of Child Neurology
- Vice-Chairman of the Guideline Drafting Committee for 'Duchenne Muscular Dystrophy Clinical Guidelines' of the Japanese Society of Neurology
- Board Certified Pediatric Neurologist
- Teaching Physician of the Japanese Society of Clinical Pharmacology and Therapeutics
Tokyo Women's Medical University Hospital, Department of Pediatrics, Associate Professor
Dr. Keiko Ishigaki
- Delegate of the Japan Pediatric Society
- Councilor of the Japanese Society of Child Neurology
- Committee Member of the Guideline Drafting Committee for 'Duchenne Muscular Dystrophy Clinical Guidelines' of the Japanese Society of Neurology
- Board Certified Pediatric Neurologist
Message from the Specialist Team
Muscular dystrophy is a field where difficulties unique to childhood overlap, from diagnosis to subsequent treatment selection and explanations to families. In recent years, due to advancements in treatment options and genetic testing, the amount of information to be considered in clinical practice has increased.
We specialists also struggle with each case daily in our practice. We would be delighted if doctors facing patients on the frontlines could utilize this window as a place to think together whenever they feel even a little lost. Please feel free to consult us.
About Medii Inc.
With the mission of 'Medical care that leaves no one behind,' Medii is tackling medical challenges primarily in fields where diagnostic technologies and treatments are highly evolving, such as rare diseases and cancer. As a solution, we provide a clinical question-solving platform that doctors can use for free.
This window aims to achieve early diagnosis and treatment optimization in pediatric muscular dystrophy, which requires high expertise for diagnosis and determining treatment policies. It establishes an environment where primary care physicians nationwide can directly consult with expert specialists.
Background
Muscular dystrophy is a designated intractable disease where muscle fibers degenerate and necrose due to genetic mutations, leading to progressive muscle weakness. There are multiple disease types, each being a rare disease with a small number of patients, and the onset timing and progression speed vary widely.
Particularly in childhood, initial symptoms such as delayed motor development or a tendency to fall can be difficult to distinguish from individual differences during the growth process. Therefore, depending on the disease type, delays in diagnosis—sometimes taking several years to reach a definitive diagnosis—have become a significant issue. Additionally, because physical and functional growth is remarkable during childhood, extremely high expertise is required to select optimal treatments and conduct long-term follow-ups according to age and developmental stages. Furthermore, providing explanations to patients and their families, such as future outlooks, requires the latest knowledge and multifaceted consideration.
In recent years, new treatment options based on genes and molecular mechanisms have emerged for certain disease types. These treatments often have specified indication conditions regarding age, disease stage, and genotype, making early diagnosis and appropriate judgment crucial.
On the other hand, the number of pediatric neurologists familiar with muscular dystrophy is limited nationwide, and it has been pointed out that access to specialists varies by region and facility. There is a need to establish a system where primary care physicians can swiftly access expert knowledge at the stage when clinical suspicion initially arises.
To address these challenges, we have opened this consultation window.
Overview of the Case Consultation Window
This window is a consultation service for doctors that primary care physicians treating pediatric muscular dystrophy can use anonymously and free of charge. Specialists provide advice based on their experience and knowledge in response to clinical questions held by primary care physicians.
Support is provided from an expert perspective at every stage of medical care, including differential diagnosis, consideration of treatment policies, interpretation of test results, age-appropriate follow-up, and methods of explaining to patients and families.
While currently targeting the pediatric phase, we plan to expand correspondence to adult clinical departments in the future.
[Related Initiatives]
Utilizing Medii E-Consult, Medii is also working in collaboration with the Japanese Society of Child Neurology to build a side-effect management system for regenerative medical products for Duchenne muscular dystrophy.
[Details] Press release dated April 23, 2026: Joint construction of a 'doctor-to-doctor collaboration system' with the Japanese Society of Child Neurology aimed at safety management of regenerative medical products for Duchenne muscular dystrophy (https://medii.jp/news/20260423)
◾️ Pediatric Muscular Dystrophy Specialist Consultation Window
URL: https://x.medii.jp/65b9bf
*This service is exclusively for doctors, and membership registration is required to use it.
*Membership registration and use of the service will continue to be provided free of charge.
◾️ Expert Specialists in Charge of This Consultation Window
National Center of Neurology and Psychiatry (NCNP), Director of Translational Medical Center / Director of Pediatric Neurology
Dr. Hirofumi Komaki
- Board Member of the Japanese Society of Child Neurology
- Vice-Chairman of the Guideline Drafting Committee for 'Duchenne Muscular Dystrophy Clinical Guidelines' of the Japanese Society of Neurology
- Board Certified Pediatric Neurologist
- Teaching Physician of the Japanese Society of Clinical Pharmacology and Therapeutics
Tokyo Women's Medical University Hospital, Department of Pediatrics, Associate Professor
Dr. Keiko Ishigaki
- Delegate of the Japan Pediatric Society
- Councilor of the Japanese Society of Child Neurology
- Committee Member of the Guideline Drafting Committee for 'Duchenne Muscular Dystrophy Clinical Guidelines' of the Japanese Society of Neurology
- Board Certified Pediatric Neurologist
Message from the Specialist Team
Muscular dystrophy is a field where difficulties unique to childhood overlap, from diagnosis to subsequent treatment selection and explanations to families. In recent years, due to advancements in treatment options and genetic testing, the amount of information to be considered in clinical practice has increased.
We specialists also struggle with each case daily in our practice. We would be delighted if doctors facing patients on the frontlines could utilize this window as a place to think together whenever they feel even a little lost. Please feel free to consult us.
About Medii Inc.
With the mission of 'Medical care that leaves no one behind,' Medii is tackling medical challenges primarily in fields where diagnostic technologies and treatments are highly evolving, such as rare diseases and cancer. As a solution, we provide a clinical question-solving platform that doctors can use for free.